CHMP Backs Six-Weekly Cemiplimab Dosing Across EU Indications
The CHMP has issued a positive opinion backing six-weekly cemiplimab dosing across all EU indications, potentially halving annual infusion visits.
Topic
Chmp
Topic
Chmp
EMA Backs First Oral IL-23 Receptor Agent for Plaque Psoriasis
The EMA's CHMP has adopted a positive opinion for the first oral IL-23 receptor-targeted therapy for plaque psoriasis, setting up…